Creo Medical (LSE:CREO) reported a strong opening to 2026, with first-quarter revenue increasing by around 60% year on year, reaching the upper end of management expectations. The performance supports its full-year guidance of 40% to 60% revenue growth, driven by continued commercial traction and growing clinical validation of its technology. At the same time, the company has agreed to divest and outsource its manufacturing operations, a move expected to reduce underlying operating costs by approximately 15% on an annualised basis compared with 2025, while enhancing scalability and efficiency.
The group is set to release its full-year 2025 results in May, which should provide further clarity on how accelerating revenue growth and cost-saving initiatives are influencing margins and cash consumption. The combination of strong top-line expansion and structural cost improvements is seen as a positive step in strengthening Creo’s position within the minimally invasive endoscopy market, and may offer investors greater confidence in its path toward sustainable profitability.
Despite this progress, the company’s broader outlook remains constrained by its financial profile, including ongoing losses and continued cash burn. While technical indicators show a supportive trend and positive momentum signals, an elevated RSI suggests the stock may be overbought in the near term. Valuation impact is neutral, as no P/E ratio or dividend yield has been disclosed.
More about Creo Medical
Creo Medical Group is a UK-listed medical technology company focused on minimally invasive surgical endoscopy solutions for pre-cancerous and cancerous conditions. Its portfolio includes advanced electrosurgical systems such as the CROMA platform, powered by Kamaptive adaptive energy technology, which aims to provide clinicians with more precise, flexible, and less invasive treatment options while improving patient outcomes and reducing procedural costs.
Leave a Reply